{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:08:42Z","timestamp":1762866522925},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,12,2]],"date-time":"2014-12-02T00:00:00Z","timestamp":1417478400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s00198-014-2940-x","type":"journal-article","created":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T14:28:08Z","timestamp":1417444088000},"page":"849-863","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Incorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan"],"prefix":"10.1007","volume":"26","author":[{"given":"H.","family":"Ohta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Solanki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,2]]},"reference":[{"key":"2940_CR1","unstructured":"National Osteoporosis Foundation (2010) Fast facts on osteoporosis. NOF web site. http:\/\/www.nof.org\/node\/40 . Accessed 17 Nov 2011"},{"key":"2940_CR2","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1359\/jbmr.1998.13.5.763","volume":"13","author":"BL Riggs","year":"1998","unstructured":"Riggs BL, Khosla S, Melton LJ III (1998) A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 13:763\u2013773","journal-title":"J Bone Miner Res"},{"key":"2940_CR3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/01.blo.0000200248.34876.fe","volume":"443","author":"OS Atik","year":"2006","unstructured":"Atik OS, Gunal I, Korkusuz F (2006) Burden of osteoporosis. Clin Orthop Relat Res 443:19\u201324","journal-title":"Clin Orthop Relat Res"},{"key":"2940_CR4","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","volume":"353","author":"JR Center","year":"1999","unstructured":"Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878\u2013882","journal-title":"Lancet"},{"key":"2940_CR5","doi-asserted-by":"crossref","first-page":"505S","DOI":"10.1016\/8756-3282(95)00258-4","volume":"17","author":"BL Riggs","year":"1995","unstructured":"Riggs BL, Melton LJ III (1995) The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17:505S\u2013511S","journal-title":"Bone"},{"key":"2940_CR6","unstructured":"International Osteoporosis Foundation (2014) Facts and statistics about osteoporosis and its impact. IOF website http:\/\/www.iofbonehealth.org\/facts-statistics . Accessed March 12, 2014."},{"key":"2940_CR7","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s001980050093","volume":"8","author":"AC Looker","year":"1998","unstructured":"Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC Jr, Lindsay R (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8:468\u2013489","journal-title":"Osteoporos Int"},{"key":"2940_CR8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11657-012-0109-9","volume":"7","author":"H Orimo","year":"2012","unstructured":"Orimo H, Nakamura T, Hosoi T, Iki M, Uenishi K, Endo N, Ohta H, Shiraki M, Sugimoto T, Suzuki T, Soen S, Nishizawa Y, Hagino H, Fukunaga M, Fujiwara S (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis\u2014executive summary. Arch Osteoporos 7:3\u201320","journal-title":"Arch Osteoporos"},{"key":"2940_CR9","volume-title":"Clinical practice guide on fracture risk in lifestyle-related diseases","author":"T Sugimoto","year":"2011","unstructured":"Sugimoto T, Fujiwara S, Hagino H, Hosoi T, Inaba M, Okazaki R, Saito M, Shiraki M, Takeuchi Y, Yamaguchi T (2011) Clinical practice guide on fracture risk in lifestyle-related diseases. Life Science Publishing Co., Ltd., Tokyo"},{"key":"2940_CR10","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/PL00004148","volume":"7","author":"B Gullberg","year":"1997","unstructured":"Gullberg B, Johnell O, Kanis JA (1997) World-wide projections for hip fracture. Osteoporos Int 7:407\u2013413","journal-title":"Osteoporos Int"},{"key":"2940_CR11","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00776-010-1543-4","volume":"15","author":"H Hagino","year":"2010","unstructured":"Hagino H, Sakamoto K, Harada A, Nakamura T, Mutoh Y, Mori S, Endo N, Nakano T, Itoi E, Kita K, Yamamoto N, Aoyagi K, Yamazaki K (2010) Nationwide one-decade survey of hip fractures in Japan. J Orthop Sci 15:737\u2013745","journal-title":"J Orthop Sci"},{"key":"2940_CR12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11657-009-0031-y","volume":"4","author":"H Orimo","year":"2009","unstructured":"Orimo H, Yaegashi Y, Onoda T, Fukushima Y, Hosoi T, Sakata K (2009) Hip fracture incidence in Japan: estimates of new patients in 2007 and 20-year trends. Arch Osteoporos 4:71\u201377","journal-title":"Arch Osteoporos"},{"key":"2940_CR13","first-page":"797","volume":"22","author":"M Iki","year":"2012","unstructured":"Iki M (2012) Epidemiology of osteoporosis in Japan. Clin Calcium 22:797\u2013803","journal-title":"Clin Calcium"},{"key":"2940_CR14","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00198-011-1627-9","volume":"23","author":"CH Bow","year":"2012","unstructured":"Bow CH, Cheung E, Cheung CL, Xiao SM, Loong C, Soong C, Tan KC, Luckey MM, Cauley JA, Fujiwara S, Kung AW (2012) Ethnic difference of clinical vertebral fracture risk. Osteoporos Int 23:879\u2013885","journal-title":"Osteoporos Int"},{"key":"2940_CR15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/gme.0b013e3181c617e6","volume":"17","author":"The North American Menopause Society","year":"2010","unstructured":"The North American Menopause Society (2010) Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 17:25\u201354","journal-title":"Menopause"},{"key":"2940_CR16","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1056\/NEJM199009273231305","volume":"323","author":"B Dawson-Hughes","year":"1990","unstructured":"Dawson-Hughes B, Dallal GE, Krall EA, Sadowski L, Sahyoun N, Tannenbaum S (1990) A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 323:878\u2013883","journal-title":"N Engl J Med"},{"key":"2940_CR17","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1210\/er.2001-7002","volume":"23","author":"B Shea","year":"2002","unstructured":"Shea B, Wells G, Cranney A, Zytaruk N, Robinson V, Griffith L, Ortiz Z, Peterson J, Adachi J, Tugwell P, Guyatt G (2002) Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev 23:552\u2013559","journal-title":"Endocr Rev"},{"key":"2940_CR18","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJMoa055218","volume":"354","author":"RD Jackson","year":"2006","unstructured":"Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, Bassford T, Beresford SA, Black HR, Blanchette P, Bonds DE, Brunner RL, Brzyski RG, Caan B, Cauley JA, Chlebowski RT, Cummings SR, Granek I, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Johnson KC, Judd H, Kotchen JM, Kuller LH, Langer RD, Lasser NL, Limacher MC, Ludlam S, Manson JE, Margolis KL, McGowan J, Ockene JK, O\u2019Sullivan MJ, Phillips L, Prentice RL, Sarto GE, Stefanick ML, Van HL, Wactawski-Wende J, Whitlock E, Anderson GL, Assaf AR, Barad D (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354:669\u2013683","journal-title":"N Engl J Med"},{"key":"2940_CR19","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1001\/jama.293.18.2257","volume":"293","author":"HA Bischoff-Ferrari","year":"2005","unstructured":"Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B (2005) Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 293:2257\u20132264","journal-title":"JAMA"},{"key":"2940_CR20","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/jbmr.2121","volume":"29","author":"JC Gallagher","year":"2014","unstructured":"Gallagher JC, Jindal P, Lynette MS (2014) Vitamin D does not increase calcium absorption in young women: a randomized clinical trial. J Bone Miner Res 29:1081\u20131087","journal-title":"J Bone Miner Res"},{"key":"2940_CR21","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/jbmr.1790","volume":"28","author":"NS Joo","year":"2013","unstructured":"Joo NS, Dawson-Hughes B, Kim YS, Oh K, Yeum KJ (2013) Impact of calcium and vitamin D insufficiencies on serum parathyroid hormone and bone mineral density: analysis of the fourth and fifth Korea National Health and Nutrition Examination Survey (KNHANES IV-3, 2009 and KNHANES V-1, 2010). J Bone Miner Res 28:764\u2013770","journal-title":"J Bone Miner Res"},{"key":"2940_CR22","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4162\/nrp.2013.7.5.409","volume":"7","author":"H Hong","year":"2013","unstructured":"Hong H, Kim EK, Lee JS (2013) Effects of calcium intake, milk and dairy product intake, and blood vitamin D level on osteoporosis risk in Korean adults: analysis of the 2008 and 2009 Korea National Health and Nutrition Examination Survey. Nutr Res Pract 7:409\u2013417","journal-title":"Nutr Res Pract"},{"key":"2940_CR23","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1507\/endocrj.EJ12-0368","volume":"60","author":"I Tatsuno","year":"2013","unstructured":"Tatsuno I, Terano T, Nakamura M, Suzuki K, Kubota K, Yamaguchi J, Yoshida T, Suzuki S, Tanaka T, Shozu M (2013) Lifestyle and osteoporosis in middle-aged and elderly women: Chiba bone survey. Endocr J 60:643\u2013650","journal-title":"Endocr J"},{"issue":"suppl 1","key":"2940_CR24","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1007\/s002239900174","volume":"59","author":"T Fujita","year":"1996","unstructured":"Fujita T (1996) Clinical guidelines for the treatment of osteoporosis in Japan. Calcif Tissue Int 59(suppl 1):S34\u2013S37","journal-title":"Calcif Tissue Int"},{"key":"2940_CR25","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1210\/jc.2004-2552","volume":"90","author":"T Matsumoto","year":"2005","unstructured":"Matsumoto T, Miki T, Hagino H, Sugimoto T, Okamoto S, Hirota T, Tanigawara Y, Hayashi Y, Fukunaga M, Shiraki M, Nakamura T (2005) A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 90:5031\u20135036","journal-title":"J Clin Endocrinol Metab"},{"key":"2940_CR26","first-page":"248","volume":"10","author":"T Matsumoto","year":"2012","unstructured":"Matsumoto T (2012) Osteoporosis treatment by a new active vitamin D3 compound, eldecalcitol, in Japan. Curr Osteoporos Rep 10:248\u2013250","journal-title":"Curr Osteoporos Rep"},{"key":"2940_CR27","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.bone.2011.07.011","volume":"49","author":"T Matsumoto","year":"2011","unstructured":"Matsumoto T, Ito M, Hayashi Y, Hirota T, Tanigawara Y, Sone T, Fukunaga M, Shiraki M, Nakamura T (2011) A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures\u2014a randomized, active comparator, double-blind study. Bone 49:605\u2013612","journal-title":"Bone"},{"key":"2940_CR28","unstructured":"Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women (review). Cochrane Database Syst Rev CD004523"},{"key":"2940_CR29","doi-asserted-by":"crossref","unstructured":"Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev CD001155","DOI":"10.1002\/14651858.CD001155.pub2"},{"key":"2940_CR30","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00198-008-0816-7","volume":"20","author":"T Matsumoto","year":"2009","unstructured":"Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T (2009) Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 20:1429\u20131437","journal-title":"Osteoporos Int"},{"key":"2940_CR31","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00198-011-1775-y","volume":"23","author":"S Silverman","year":"2012","unstructured":"Silverman S, Christiansen C (2012) Individualizing osteoporosis therapy. Osteoporos Int 23:797\u2013809","journal-title":"Osteoporos Int"},{"key":"2940_CR32","first-page":"18","volume":"64","author":"JP Schneider","year":"2009","unstructured":"Schneider JP (2009) Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. Geriatrics 64:18\u201323","journal-title":"Geriatrics"},{"key":"2940_CR33","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","volume":"25","author":"E Shane","year":"2010","unstructured":"Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O\u2019Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267\u20132294","journal-title":"J Bone Miner Res"},{"key":"2940_CR34","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/j.joms.2011.03.051","volume":"69","author":"M Urade","year":"2011","unstructured":"Urade M, Tanaka N, Furusawa K, Shimada J, Shibata T, Kirita T, Yamamoto T, Ikebe T, Kitagawa Y, Fukuta J (2011) Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan. J Oral Maxillofac Surg 69:e364\u2013e371","journal-title":"J Oral Maxillofac Surg"},{"key":"2940_CR35","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/gut.2005.080358","volume":"55","author":"GM Naylor","year":"2006","unstructured":"Naylor GM, Gotoda T, Dixon M, Shimoda T, Gatta L, Owen R, Tompkins D, Axon A (2006) Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. Gut 55:1545\u20131552","journal-title":"Gut"},{"key":"2940_CR36","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00223-013-9734-6","volume":"93","author":"T Nakamura","year":"2013","unstructured":"Nakamura T, Nakano T, Ito M, Hagino H, Hashimoto J, Tobinai M, Mizunuma H (2013) Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg\/month intravenous ibandronate versus 2.5 mg\/day oral risedronate in patients with primary osteoporosis. Calcif Tissue Int 93:137\u2013146","journal-title":"Calcif Tissue Int"},{"key":"2940_CR37","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2796.2008.02010.x","volume":"264","author":"S Boonen","year":"2008","unstructured":"Boonen S, Vanderschueren D, Venken K, Milisen K, Delforge M, Haentjens P (2008) Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance. J Intern Med 264:315\u2013332","journal-title":"J Intern Med"},{"key":"2940_CR38","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00774-006-0735-7","volume":"25","author":"EG Pasion","year":"2007","unstructured":"Pasion EG, Sivananthan SK, Kung AW, Chen SH, Chen YJ, Mirasol R, Tay BK, Shah GA, Khan MA, Tam F, Hall BJ, Thiebaud D (2007) Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women. J Bone Miner Metab 25:105\u2013113","journal-title":"J Bone Miner Metab"},{"key":"2940_CR39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0002-9343(03)00362-0","volume":"115","author":"AN Tosteson","year":"2003","unstructured":"Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209\u2013216","journal-title":"Am J Med"},{"key":"2940_CR40","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00198-012-1984-z","volume":"24","author":"YK Soong","year":"2013","unstructured":"Soong YK, Tsai KS, Huang HY, Yang RS, Chen JF, Wu PC, Huang KE (2013) Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan. Osteoporos Int 24:511\u2013521","journal-title":"Osteoporos Int"},{"key":"2940_CR41","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","volume":"81","author":"ES Siris","year":"2006","unstructured":"Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013\u20131022","journal-title":"Mayo Clin Proc"},{"key":"2940_CR42","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00198-011-1782-z","volume":"23","author":"R Okazaki","year":"2012","unstructured":"Okazaki R, Hagino H, Ito M, Sone T, Nakamura T, Mizunuma H, Fukunaga M, Shiraki M, Nishizawa Y, Ohashi Y, Matsumoto T (2012) Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis. Osteoporos Int 23:1737\u20131745","journal-title":"Osteoporos Int"},{"key":"2940_CR43","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.bone.2009.02.016","volume":"44","author":"H Hagino","year":"2009","unstructured":"Hagino H, Nishizawa Y, Sone T, Morii H, Taketani Y, Nakamura T, Itabashi A, Mizunuma H, Ohashi Y, Shiraki M, Minamide T, Matsumoto T (2009) A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone 44:1078\u20131084","journal-title":"Bone"},{"key":"2940_CR44","doi-asserted-by":"crossref","unstructured":"Ikeda S, Sakai A, Okimoto N, Teshima K, Arita S, Matsumoto H, Tsurukami H, Okazaki Y, Nagashima M, Fukuda F, Yoshioka T Patient preference and adherence to once-monthly oral minodronate in Japanese osteoporotic patients previously using daily or weekly bisphosphonates [abstract]. Presented at: Annual Congress of the European Calcified Tissue Society; May 18\u201321, 2013; Lisbon, Portugal","DOI":"10.1530\/boneabs.1.PP415"},{"key":"2940_CR45","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1007\/s00198-011-1868-7","volume":"23","author":"AS Carmel","year":"2012","unstructured":"Carmel AS, Shieh A, Bang H, Bockman RS (2012) The 25(OH)D level needed to maintain a favorable bisphosphonate response is >\/=33 ng\/ml. Osteoporos Int 23:2479\u20132487","journal-title":"Osteoporos Int"},{"key":"2940_CR46","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1185\/03007995.2011.580341","volume":"27","author":"H Orimo","year":"2011","unstructured":"Orimo H, Nakamura T, Fukunaga M, Ohta H, Hosoi T, Uemura Y, Kuroda T, Miyakawa N, Ohashi Y, Shiraki M (2011) Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02. Curr Med Res Opin 27:1273\u20131284","journal-title":"Curr Med Res Opin"},{"key":"2940_CR47","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bone.2012.03.026","volume":"51","author":"P Peris","year":"2012","unstructured":"Peris P, Martinez-Ferrer A, Monegal A, Martinez de Osaba MJ, Muxi A, Guanabens N (2012) 25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis. Bone 51:54\u201358","journal-title":"Bone"},{"key":"2940_CR48","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","volume":"290","author":"JA Cauley","year":"2003","unstructured":"Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women\u2019s Health Initiative randomized trial. JAMA 290:1729\u20131738","journal-title":"JAMA"},{"key":"2940_CR49","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1359\/jbmr.060312","volume":"21","author":"RD Jackson","year":"2006","unstructured":"Jackson RD, Wactawski-Wende J, LaCroix AZ, Pettinger M, Yood RA, Watts NB, Robbins JA, Lewis CE, Beresford SA, Ko MG, Naughton MJ, Satterfield S, Bassford T (2006) Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women\u2019s health initiative randomized trial. J Bone Miner Res 21:817\u2013828","journal-title":"J Bone Miner Res"},{"key":"2940_CR50","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1210\/er.2001-5002","volume":"23","author":"G Wells","year":"2002","unstructured":"Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N, Robinson V, Henry D, O\u2019Connell D, Cranney A (2002) Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 23:529\u2013539","journal-title":"Endocr Rev"},{"key":"2940_CR51","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","volume":"291","author":"GL Anderson","year":"2004","unstructured":"Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O\u2019Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van HL, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women\u2019s Health Initiative randomized controlled trial. JAMA 291:1701\u20131712","journal-title":"JAMA"},{"key":"2940_CR52","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women\u2019s Health Initiative randomized controlled trial. JAMA 288:321\u2013333","journal-title":"JAMA"},{"key":"2940_CR53","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/gme.0b013e3181d0f6b9","volume":"17","author":"The North American Menopause Society","year":"2010","unstructured":"The North American Menopause Society (2010) Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 17:242\u2013255","journal-title":"Menopause"},{"key":"2940_CR54","first-page":"686","volume":"83","author":"DF Archer","year":"1994","unstructured":"Archer DF, Pickar JH, Bottiglioni F (1994) Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol 83:686\u2013692","journal-title":"Obstet Gynecol"},{"key":"2940_CR55","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/j.1471-0528.2007.01537.x","volume":"114","author":"ML Hammar","year":"2007","unstructured":"Hammar ML, van de Weijer P, Franke HR, Pornel B, von Mauw EM, Nijland EA (2007) Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. BJOG 114:1522\u20131529","journal-title":"BJOG"},{"key":"2940_CR56","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0378-5122(96)01067-5","volume":"25","author":"C Nagata","year":"1996","unstructured":"Nagata C, Matsushita Y, Shimizu H (1996) Prevalence of hormone replacement therapy and user\u2019s characteristics: a community survey in Japan. Maturitas 25:201\u2013207","journal-title":"Maturitas"},{"key":"2940_CR57","first-page":"198","volume":"21","author":"H Yamauchi","year":"2003","unstructured":"Yamauchi H, Suzuki H, Orimo H (2003) Calcitonin for the treatment of osteoporosis: dosage and dosing interval in Japan. J Bone Miner Metab 21:198\u2013204","journal-title":"J Bone Miner Metab"},{"key":"2940_CR58","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s007760200114","volume":"7","author":"J Iwamoto","year":"2002","unstructured":"Iwamoto J, Takeda T, Ichimura S, Uzawa M (2002) Effects of 5-year treatment with elcatonin and alfacalcidol on lumbar bone mineral density and the incidence of vertebral fractures in postmenopausal women with osteoporosis: a retrospective study. J Orthop Sci 7:637\u2013643","journal-title":"J Orthop Sci"},{"key":"2940_CR59","first-page":"9","volume":"3","author":"K Yoh","year":"2012","unstructured":"Yoh K, Uzawa T, Orito T, Tanaka K (2012) Improvement of Quality of Life (QOL) in osteoporotic patients by elcatonin treatment: a trial taking the participants\u2019 preference into account. Jpn Clin Med 3:9\u201314","journal-title":"Jpn Clin Med"},{"key":"2940_CR60","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00198-013-2516-1","volume":"25","author":"T Sugimoto","year":"2014","unstructured":"Sugimoto T, Nakamura T, Nakamura Y, Isogai Y, Shiraki M (2014) Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis. Osteoporos Int 25:1173\u20131180","journal-title":"Osteoporos Int"},{"key":"2940_CR61","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441","journal-title":"N Engl J Med"},{"key":"2940_CR62","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1210\/jc.2011-3479","volume":"97","author":"T Nakamura","year":"2012","unstructured":"Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M (2012) Randomized Teriparatide [human parathyroid hormone (PTH) 1\u201334] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097\u20133106","journal-title":"J Clin Endocrinol Metab"},{"key":"2940_CR63","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1185\/03007995.2012.761956","volume":"29","author":"T Sugimoto","year":"2013","unstructured":"Sugimoto T, Shiraki M, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Kuroda T, Nakamura T (2013) Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial. Curr Med Res Opin 29:195\u2013203","journal-title":"Curr Med Res Opin"},{"key":"2940_CR64","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00774-012-0403-z","volume":"31","author":"T Yamamoto","year":"2013","unstructured":"Yamamoto T, Tsujimoto M, Hamaya E, Sowa H (2013) Assessing the effect of baseline status of serum bone turnover markers and vitamin D levels on efficacy of teriparatide 20 mug\/day administered subcutaneously in Japanese patients with osteoporosis. J Bone Miner Metab 31:199\u2013205","journal-title":"J Bone Miner Metab"},{"key":"2940_CR65","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00774-013-0505-2","volume":"32","author":"T Nakano","year":"2014","unstructured":"Nakano T, Shiraki M, Sugimoto T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Kuroda T, Nakamura T (2014) Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial. J Bone Miner Metab 32:441\u2013446","journal-title":"J Bone Miner Metab"},{"key":"2940_CR66","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San MJ, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"2940_CR67","author":"T Nakamura","year":"2014","unstructured":"Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Sone T, Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Shiraki M, Fukunaga M (2014) Fracture risk reduction with denosumab in japanese postmenopausal women and men with osteoporosis: Denosumab fracture Intervention RandomizEd placebo Controlled Trial (DIRECT). J Clin Endocrinol Metab. doi: 10.1210\/jc.2013-4175","journal-title":"J Clin Endocrinol Metab"},{"key":"2940_CR68","unstructured":"Prolia [package insert] (2013) Amgen Inc., Thousand Oaks, CA"},{"key":"2940_CR69","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1210\/rp.57.1.295","volume":"57","author":"DP McDonnell","year":"2002","unstructured":"McDonnell DP, Connor CE, Wijayaratne A, Chang CY, Norris JD (2002) Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist\/antagonist activities of selective estrogen receptor modulators. Recent Prog Horm Res 57:295\u2013316","journal-title":"Recent Prog Horm Res"},{"key":"2940_CR70","first-page":"637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282:637\u2013645","journal-title":"Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA"},{"key":"2940_CR71","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s00774-006-0702-3","volume":"24","author":"T Nakamura","year":"2006","unstructured":"Nakamura T, Liu JL, Morii H, Huang QR, Zhu HM, Qu Y, Hamaya E, Thiebaud D (2006) Effect of raloxifene on clinical fractures in Asian women with postmenopausal osteoporosis. J Bone Miner Metab 24:414\u2013418","journal-title":"J Bone Miner Metab"},{"key":"2940_CR72","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s00774-012-0365-1","volume":"30","author":"N Iikuni","year":"2012","unstructured":"Iikuni N, Hamaya E, Nihojima S, Yokoyama S, Goto W, Taketsuna M, Miyauchi A, Sowa H (2012) Safety and effectiveness profile of raloxifene in long-term, prospective, postmarketing surveillance. J Bone Miner Metab 30:674\u2013682","journal-title":"J Bone Miner Metab"},{"key":"2940_CR73","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1185\/03007995.2012.736860","volume":"28","author":"K Yoh","year":"2012","unstructured":"Yoh K, Hamaya E, Urushihara H, Iikuni N, Yamamoto T, Taketsuna M, Miyauchi A, Sowa H, Tanaka K (2012) Quality of life in raloxifene-treated Japanese women with postmenopausal osteoporosis: a prospective, postmarketing observational study. Curr Med Res Opin 28:1757\u20131766","journal-title":"Curr Med Res Opin"},{"key":"2940_CR74","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1185\/030079905X61839","volume":"21","author":"S Martino","year":"2005","unstructured":"Martino S, Disch D, Dowsett SA, Keech CA, Mershon JL (2005) Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin 21:1441\u20131452","journal-title":"Curr Med Res Opin"},{"key":"2940_CR75","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJMoa0808692","volume":"362","author":"SR Cummings","year":"2010","unstructured":"Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong RA, Thompson DD, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R (2010) Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 362:686\u2013696","journal-title":"N Engl J Med"},{"key":"2940_CR76","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/gme.0b013e3181e84bb4","volume":"18","author":"SR Goldstein","year":"2011","unstructured":"Goldstein SR, Neven P, Cummings S, Colgan T, Runowicz CD, Krpan D, Proulx J, Johnson M, Thompson D, Thompson J, Sriram U (2011) Postmenopausal evaluation and risk reduction with lasofoxifene (PEARL) trial: 5-year gynecological outcomes. Menopause 18:17\u201322","journal-title":"Menopause"},{"key":"2940_CR77","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1749-6632.2001.tb04039.x","volume":"949","author":"BS Komm","year":"2001","unstructured":"Komm BS, Lyttle CR (2001) Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann N Y Acad Sci 949:317\u2013326","journal-title":"Ann N Y Acad Sci"},{"key":"2940_CR78","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1210\/en.2008-0817","volume":"149","author":"Y Kharode","year":"2008","unstructured":"Kharode Y, Bodine PV, Miller CP, Lyttle CR, Komm BS (2008) The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 149:6084\u20136091","journal-title":"Endocrinology"},{"key":"2940_CR79","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1210\/en.2005-0030","volume":"146","author":"BS Komm","year":"2005","unstructured":"Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR (2005) Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 146:3999\u20134008","journal-title":"Endocrinology"},{"key":"2940_CR80","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.bone.2011.05.024","volume":"49","author":"BS Komm","year":"2011","unstructured":"Komm BS, Vlasseros F, Samadfam R, Chouinard L, Smith SY (2011) Skeletal effects of bazedoxifene paired with conjugated estrogens in ovariectomized rats. Bone 49:376\u2013386","journal-title":"Bone"},{"key":"2940_CR81","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1124\/dmd.108.021808","volume":"36","author":"C Prakash","year":"2008","unstructured":"Prakash C, Johnson KA, Schroeder CM, Potchoiba MJ (2008) Metabolism, distribution, and excretion of a next generation selective estrogen receptor modulator, lasofoxifene, in rats and monkeys. Drug Metab Dispos 36:1753\u20131769","journal-title":"Drug Metab Dispos"},{"key":"2940_CR82","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.mce.2008.01.027","volume":"287","author":"JS Crabtree","year":"2008","unstructured":"Crabtree JS, Peano BJ, Zhang X, Komm BS, Winneker RC, Harris HA (2008) Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland. Mol Cell Endocrinol 287:40\u201346","journal-title":"Mol Cell Endocrinol"},{"key":"2940_CR83","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1210\/en.2008-1210","volume":"150","author":"BJ Peano","year":"2009","unstructured":"Peano BJ, Crabtree JS, Komm BS, Winneker RC, Harris HA (2009) Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology 150:1897\u20131903","journal-title":"Endocrinology"},{"key":"2940_CR84","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jsbmb.2009.11.003","volume":"118","author":"KC Chang","year":"2010","unstructured":"Chang KC, Wang Y, Bodine PV, Nagpal S, Komm BS (2010) Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens. J Steroid Biochem Mol Biol 118:117\u2013124","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2940_CR85","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1359\/jbmr.071206","volume":"23","author":"PD Miller","year":"2008","unstructured":"Miller PD, Chines AA, Christiansen C, Hoeck HC, Kendler DL, Lewiecki EM, Woodson G, Levine AB, Constantine G, Delmas PD (2008) Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 23:525\u2013535","journal-title":"J Bone Miner Res"},{"key":"2940_CR86","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/gme.0b013e3181a816be","volume":"16","author":"JV Pinkerton","year":"2009","unstructured":"Pinkerton JV, Archer DF, Utian WH, Menegoci JC, Levine AB, Chines AA, Constantine GD (2009) Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. Menopause 16:1102\u20131108","journal-title":"Menopause"},{"key":"2940_CR87","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/gme.0b013e3181a818db","volume":"16","author":"DF Archer","year":"2009","unstructured":"Archer DF, Pinkerton JV, Utian WH, Menegoci JC, de Villiers TJ, Yuen CK, Levine AB, Chines AA, Constantine GD (2009) Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 16:1109\u20131115","journal-title":"Menopause"},{"key":"2940_CR88","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1471-2474-11-130","volume":"11","author":"C Christiansen","year":"2010","unstructured":"Christiansen C, Chesnut CH III, Adachi JD, Brown JP, Fernandes CE, Kung AW, Palacios S, Levine AB, Chines AA, Constantine GD (2010) Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskelet Disord 11:130","journal-title":"BMC Musculoskelet Disord"},{"key":"2940_CR89","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","volume":"23","author":"SL Silverman","year":"2008","unstructured":"Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 23:1923\u20131934","journal-title":"J Bone Miner Res"},{"key":"2940_CR90","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00198-010-1302-6","volume":"22","author":"TJ Villiers de","year":"2011","unstructured":"de Villiers TJ, Chines AA, Palacios S, Lips P, Sawicki AZ, Levine AB, Codreanu C, Kelepouris N, Brown JP (2011) Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 22:567\u2013576","journal-title":"Osteoporos Int"},{"key":"2940_CR91","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00198-011-1691-1","volume":"23","author":"SL Silverman","year":"2012","unstructured":"Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjaerg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD (2012) Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 23:351\u2013363","journal-title":"Osteoporos Int"},{"key":"2940_CR92","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.maturitas.2013.06.008","volume":"76","author":"S Palacios","year":"2013","unstructured":"Palacios S, de Villiers TJ, Nardone FC, Levine AB, Williams R, Hines T, Mirkin S, Chines AA (2013) Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study. Maturitas 76:81\u201387","journal-title":"Maturitas"},{"key":"2940_CR93","unstructured":"Palacios S, Silverman S, Levine AB Long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled study [abstract 973]. Presented at: the International Menopause Society World Congress on Menopause; June 8\u201311, 2011; Rome Italy"},{"key":"2940_CR94","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/jbmr.252","volume":"26","author":"A Itabashi","year":"2011","unstructured":"Itabashi A, Yoh K, Chines AA, Miki T, Takada M, Sato H, Gorai I, Sugimoto T, Mizunuma H, Ochi H, Constantine GD, Ohta H (2011) Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal Japanese women with osteoporosis. J Bone Miner Res 26:519\u2013529","journal-title":"J Bone Miner Res"},{"key":"2940_CR95","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bone.2009.02.014","volume":"44","author":"JA Kanis","year":"2009","unstructured":"Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44:1049\u20131054","journal-title":"Bone"},{"issue":"suppl 1","key":"2940_CR96","first-page":"S140","volume":"24","author":"E McCloskey","year":"2009","unstructured":"McCloskey E, Johansson H, Oden A, Chines A, Kanis J (2009) Assessment of the effect of bazedoxifene on non-vertebral fracture risk [abstract FR0376]. J Bone Miner Res 24(suppl 1):S140","journal-title":"J Bone Miner Res"},{"issue":"suppl 4","key":"2940_CR97","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0049-3848(09)70136-7","volume":"123","author":"RH White","year":"2009","unstructured":"White RH, Keenan CR (2009) Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb Res 123(suppl 4):S11\u2013S17","journal-title":"Thromb Res"},{"key":"2940_CR98","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/gme.0b013e3181a7fb1e","volume":"16","author":"JA Harvey","year":"2009","unstructured":"Harvey JA, Holm MK, Ranganath R, Guse PA, Trott EA, Helzner E (2009) The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis. Menopause 16:1193\u20131196","journal-title":"Menopause"},{"key":"2940_CR99","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3109\/09513590.2012.679062","volume":"28","author":"S Palacios","year":"2012","unstructured":"Palacios S, Christiansen C, Sanchez BR, Gambacciani M, Hadji P, Karsdal M, Lambrinoudaki I, Lello S, O\u2019Beirne B, Romao F, Rozenberg S, Stevenson JC, Ben-Rafael Z (2012) Recommendations on the management of fragility fracture risk in women younger than 70 years. Gynecol Endocrinol 28:770\u2013786","journal-title":"Gynecol Endocrinol"},{"key":"2940_CR100","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927\u20132938","journal-title":"JAMA"},{"key":"2940_CR101","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11914-009-0003-6","volume":"7","author":"P Geusens","year":"2009","unstructured":"Geusens P (2009) Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment. Curr Osteoporos Rep 7:12\u201317","journal-title":"Curr Osteoporos Rep"},{"key":"2940_CR102","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJM199212033272305","volume":"327","author":"MC Chapuy","year":"1992","unstructured":"Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ (1992) Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 327:1637\u20131642","journal-title":"N Engl J Med"},{"key":"2940_CR103","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1056\/NEJM199709043371003","volume":"337","author":"B Dawson-Hughes","year":"1997","unstructured":"Dawson-Hughes B, Harris SS, Krall EA, Dallal GE (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337:670\u2013676","journal-title":"N Engl J Med"},{"key":"2940_CR104","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.3390\/nu5072522","volume":"5","author":"IR Reid","year":"2013","unstructured":"Reid IR (2013) Cardiovascular effects of calcium supplements. Nutrients 5:2522\u20132529","journal-title":"Nutrients"},{"key":"2940_CR105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF01771801","volume":"13","author":"Y Nishizawa","year":"1995","unstructured":"Nishizawa Y, Hagiwara S, Nakatsuka K, Aratani H, Miki T, Morii H (1995) Efficacy of low-dose, intermittent eel calcitonin treatment for osteoporosis. J Bone Miner Metab 13:23\u201326","journal-title":"J Bone Miner Metab"},{"key":"2940_CR106","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF01768835","volume":"14","author":"H Orimo","year":"1996","unstructured":"Orimo H, Morii H, Inoue T, Yamamoto K, Minaguchi H, Ishii Y, Murota K, Fujimaki E, Watanabe R, Harata S, Honjo H, Fujita T (1996) Effect of elcatonin on involutional osteoporosis. J Bone Miner Metab 14:73\u201378","journal-title":"J Bone Miner Metab"},{"key":"2940_CR107","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3760\/cma.j.issn.0366-6999.20121626","volume":"126","author":"Y Li","year":"2013","unstructured":"Li Y, Xuan M, Wang B, Yang J, Zhang H, Zhang XZ, Guo XH, Lu XF, Xue QY, Yang GY, Ji QH, Liu ZM, Li CJ, Wu TF, Sheng ZY, Li PQ, Tong JC (2013) Comparison of parathyroid hormone (1\u201334) and elcatonin in postmenopausal women with osteoporosis: an 18-month randomized, multicenter controlled trial in China. Chin Med J (Engl) 126:457\u2013463","journal-title":"Chin Med J (Engl)"},{"key":"2940_CR108","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","volume":"355","author":"E Barrett-Connor","year":"2006","unstructured":"Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125\u2013137","journal-title":"N Engl J Med"},{"key":"2940_CR109","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/STROKEAHA.108.518621","volume":"40","author":"L Mosca","year":"2009","unstructured":"Mosca L, Grady D, Barrett-Connor E, Collins P, Wenger N, Abramson BL, Paganini-Hill A, Geiger MJ, Dowsett SA, Amewou-Atisso M, Kornitzer M (2009) Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke 40:147\u2013155","journal-title":"Stroke"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-014-2940-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-014-2940-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-014-2940-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T13:05:14Z","timestamp":1717592714000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-014-2940-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,2]]},"references-count":109,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["2940"],"URL":"https:\/\/doi.org\/10.1007\/s00198-014-2940-x","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,2]]}}}